SUMMARY Forty four children with recurrent obstructive episodes after acute bronchiolitis in infancy were treated with nebulised beclomethasone dipropionate or placebo for eight weeks in a randomised double-blind study. They were seen monthly for a year afterwards, and also if they had acute respiratory illnesses with or without bronchopulmonary obstruction. The two treatment groups were well matched. The children receiving active treatment had significantly fewer symptomatic respiratory illnesses and fewer episodes of bronchopulmonary obstruction during the follow up period. The children given placebo had significantly higher obstructive scores during the study period, and they were treated with inhaled P2 agonists and theophylline for longer periods of time during the follow up period.
Acute bronchiolitis in infancy is most often associated with respiratory syncytial virus infection, and is associated with later episodes of bronchopulmonary obstruction and the development ofbronchial asthma in children.' 2 Inhalation of beclomethasone dipropionate, as an aerosol or as powder, is effective and safe prophylaxis of childhood asthma,3 4 possibly because it reduces the non-specific bronchial hyperreactivity in asthma.5 As the use of both aerosols and powder inhalation is difficult in infants and small children, we have investigated whether nebulised beclomethasone dipropionate could be used in infants and small children with recurrent episodes of bronchopulmonary obstruction after acute bronchiolitis, and whether treatment with beclomethasone dipropionate for eight weeks could possibly influence the outcome. We have therefore conducted a placebo controlled double blind study in children under 2 years of age to study the effect of inhaled nebulised beclomethasone dipropionate for eight weeks with a follow up period of one year. The aim of the study was to examine whether inhalation of nebulised beclomethasone dipropionate influenced the frequency of recurrent attacks of bronchopulmonary obstruction during treatment, as well as the subsequent development of episodes after the treatment.
Patients and methods
A total of44 children aged between six and 24 months were randomly allocated to be treated by placebo (n=22) or beclomethasone dipropionate (n=22) in a double blind manner. To be included in the study the patients had to fulfil the following criteria: they had to be previously admitted to the paediatric department of Ullev'al hospital (the municipal hospital of Oslo) with acute bronchiolitis, and they had to have had a history of at least one attack of bronchopulmonary obstruction after the initial attack of bronchiolitis. The diagnosis of bronchiolitis was made according to the criteria of Court.6 treatment and received a dose of 2 ml four times daily for the first two weeks, and then 2 ml twice daily for the remaining six weeks. The patients also received additional treatment for bronchopulmonary obstruction according to the standard clinical practice of the hospital. During the follow up period the patients were seen regularly each month, and on additional occasions if they had an acute respiratory illness with or without bronchopulmonary obstruction. Whenever they were seen a questionnaire was filled in by the examining doctor, and a score of the degree of bronchopulmonary obstruction was obtained during acute attacks (table 2). The maximum possible score at any one visit was 15.
At the end of the study period allergic reactions were sought by skin test, radioallergosorbent test (Phadebas, RAST), and measurement of total IgE (Phadebas, PRIST). The skin test and the RAST tests were carried out as reported in a previous study.7
When respiratory tract illnesses occurred, nasopharyngeal aspirates were obtained and examined for respiratory viruses by rapid immunofluorescence and cell culture as previously described.7 This was also done during hospital admissions before the study.
The results are given as medians with 95% confidence intervals calculated by the BernoulliWilcoxon method.8 
Results
Twenty two children were randomised to receive placebo and 22 to receive beclomethasone dipropionate. There were no significant differences between the two treatment groups in the incidence of neonatal respiratory disease (p=0-31), or allergic disease among the mothers (p=0-52), the fathers (p=0-40), the siblings (p=0-31), or the grandparents of the patients (p=052). This was true also for other pre-existing diseases among parents, siblings, and grandparents. In addition no significant differences were found for family relationship (p=047), number of siblings (p=0.40), hygienic state of the home (p=0.20), floor covering in the homes (carpets or not) (p=055), pets in the home (p=0-12), place of stay during the day (for example, kindergarten, nursery, at home) (p=066), and tobacco smoking in the home (p=0.95). Other background variables are given in table 1. The children in the placebo group were generally older and heavier than the treated children at the time of inclusion in the study. They also had more acute respiratory tract illnesses before their entry in the study, though the difference was not significant. There (table 3) . The same was found for theophylline (usually given rectally or orally) (table 3) .
Total IgE did not differ between the two groups at the end of the study (table 3) . Six children in the placebo group and one child in the beclomethasone dipropionate group had positive RASTs at the end of the study, whereas four children in the placebo group and one child in the beclomethasone dipropionate group had positive skin tests at the end of the study. These differences were not significant.
Discussion
The association between bronchiolitis in infancy and subsequent obstructive airways disease1 2 may be a result of increased bronchial hyper-reactivity as 
